Chelsea Therapeutics International, Ltd.(CHTP)- NASDAQ
CHTP is defunct.
  • May 8, 2014, 12:48 PM
    | May 8, 2014, 12:48 PM
  • May 8, 2014, 9:16 AM
    | May 8, 2014, 9:16 AM
  • May 8, 2014, 8:36 AM
    • By acquiring Chelsea Therapeutics (CHTP), Lundbeck (HLUKF) gains the rights to Chelsea's Northera treatment for neurogenic orthostatic hypotension, a disease that is associated with neurological disorders such as Parkinson's.
    • Northera recently won FDA approval and is due to be launched later this year.
    • Lundbeck's offer of $7.94 a share comprises $6.44 a share in cash and up to $1.50 of contingent value rights (CVRs) that will be related to Northera's commercial performance.
    • The transaction is expected to close in Q3.
    • Chelsea Therapeutics' shares are +32% at $6.60. (PR)
    • Previous
    | May 8, 2014, 8:36 AM | 3 Comments
  • Mar. 13, 2014, 1:58 PM
    | Mar. 13, 2014, 1:58 PM | 2 Comments
  • Feb. 19, 2014, 12:45 PM
    | Feb. 19, 2014, 12:45 PM | 1 Comment
  • Feb. 19, 2014, 9:38 AM
    • Deutsche Bank raises its price target for Chelsea Therapeutics (CHTP) to $8 following the FDA's approval of the company's Northera treatment. Needham ups its target to $10.
    • Shares are surging 33% to $6.61.
    • The drug is indicated for preventing sudden drops in blood pressure, which can lead to dizziness and fainting, in patients with neurogenic orthostatic hypotension, a disease that is associated with neurological disorders such as Parkinson's.
    • Wedbush analyst Liana Moussatos expects the company to explore partnerships or to even be acquired, although it could launch Northera on its own. Moussatos estimates that the treatment could generate $430M in global peak sales.
    • The FDA authorized Northera on an "accelerated basis", which means patients will get access to it while the company carries out a post-market study of 1,400 people to see whether Northera has a durable effect - efficacy beyond two weeks has yet to be demonstrated.
    | Feb. 19, 2014, 9:38 AM | 6 Comments
  • Feb. 19, 2014, 9:13 AM
    | Feb. 19, 2014, 9:13 AM
  • Feb. 18, 2014, 5:35 PM
    • Chelsea Therapeutics (CHTP) resumes trading after being halted following the FDA's approval of Northera; shares now +35.5% after trading 33%-40% higher since restarting at 5:25.
    | Feb. 18, 2014, 5:35 PM | 1 Comment
  • Feb. 18, 2014, 9:13 AM
    | Feb. 18, 2014, 9:13 AM | 1 Comment
  • Feb. 14, 2014, 7:07 PM
    • The suspense continues: Chelsea Therapeutics (CHTP) says the FDA has notified it that the decision date for the Northera new drug application has been extended to Feb. 18 due to an office closure caused by severe weather.
    • Shares, which had been down more than 20% AH, now +1.4%.
    | Feb. 14, 2014, 7:07 PM | 15 Comments
  • Feb. 14, 2014, 4:10 PM
    • With nervous Chelsea Therapeutics (CHTP -4%) still awaiting word from the FDA on Northera, Deutshce Bank's Robyn Karnauskas sees fair value for the stock in the $8-$9 range if the drug is approved and - more or less - $0 for the shares if declined.
    • Her team is modeling market share of 50% and peak sales of about $550M worldwide. Possibly higher market share and peak sales of about $780M could bring the stock up to the $12-$13 area.
    • Cash on the balance sheet in the case of non-approval is $21M, or $0.27 per share.
    | Feb. 14, 2014, 4:10 PM | 16 Comments
  • Feb. 12, 2014, 10:29 AM
    • Chelsea Therapeutics (CHTP +2.6%) is 70% likely to win FDA approval Friday for its Northera treatment of neurogenic orthostatic hypotension, Adam Feuerstein predicts, adding that there's a small chance of a delay given the short time period between Friday's approval decision date and last month's positive advisory panel.
    • A Northera approval would be good news as long as the FDA doesn't saddle the drug with significant use restrictions; an FDA-approved label which says Northera should not be used longer than a week or two would be a disappointment.
    | Feb. 12, 2014, 10:29 AM | 1 Comment
  • Jan. 15, 2014, 9:40 AM
    • The sell-side continues to weigh in on Chelsea Therapeutics (CHTP +125.2%) following Thursday's Northera panel.
    • Deutsche's Robyn Karnauskas lifts her target to $5 from $4, but notes the FDA could still decide against approval. Fair value is $8-9 assuming approval.
    • Meanwhile, Wedbush is out reiterating an Outperform rating and an $8 target. "Our impression was that the panel came to appreciate the vagaries of clinical trials for neurological disorders—especially in orphan diseases like NOH," analyst Liana Moussatos says.
    | Jan. 15, 2014, 9:40 AM | 2 Comments
  • Jan. 15, 2014, 9:11 AM
    | Jan. 15, 2014, 9:11 AM
  • Jan. 15, 2014, 7:50 AM
    • Shares of Chelsea Therapeutics (CHTP) look set for a spectacular session on the back of Tuesday's positive Ad Com for Northera.
    • The company says it is "appreciative of the FDA bringing [the] Northera NDA before the Cardiovascular and Renal Drugs Advisory Committee, and for the Committee's thoughtful discussion of the application." (PR)
    • Needham says the vote "represents a meaningful reduction in risk to the potential commercialization of Northera."
    • Analyst Alan Carr lifts his price target on the shares to $8 from $4. Carr does say that "a degree of caution may [still] be prudent until the FDA responds, however, given strength of regulatory opposition to the drug to date."
    • CHTP +160% premarket
    | Jan. 15, 2014, 7:50 AM
  • Jan. 10, 2014, 1:19 PM
    • Wedbush is out in defense of Chelsea Therapeutics (CHTP -31.3%) amid a steep sell-off triggered by the release of Northera briefing docs.
    • "The reviewers brought up no material new arguments against approval, in our view," analyst Liana Moussatos says, adding that "the previous panel recommended approval (7-4) —so we anticipate the panel on January 14th is likely to also recommend approval."
    • Price target is $8.
    | Jan. 10, 2014, 1:19 PM | 20 Comments
Company Description
Chelsea Therapeutics International, Ltd., is a pharmaceutical company focused on acquisition, development and commercialization of pharmaceutical products for the treatment of a variety of human diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States